BJG-05-039
Based on 1 Customer Validation
BJG-05-039 is an inhibitor targeting PAK1, with an IC50 of 233 nM against human PAK1. BJG-05-039 induces the selective degradation of PAK1 and inhibits its kinase activity by conjugating NVS-PAK1-1 (HY-100519) with Lenalidomide (HY-A0003) to recruit Cereblon. BJG-05-039 can be used in research related to breast cancer and ovarian cancer.
For research use only. We do not sell to patients.
- Purity : 98.06%
- CAS No.: 3009849-06-0
- Formula: C41H44ClF3N8O5
- Molecular Weight:821.29
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
PAK1 233 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | EC50 |
0.086 μM
|
Antiproliferative activity against human MCF7 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human MCF7 breast cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
36416208 |
| OVCAR-3 | EC50 |
0.1 μM
|
Antiproliferative activity against human OVCAR3 ovarian cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
Antiproliferative activity against human OVCAR3 ovarian cancer cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay.
|
36416208 |
In Vitro
BJG-05-039 (10-dose 3-fold serial dilution starting at 1 μM; 60 minutes) potently and selectively inhibits recombinant human PAK1 kinase activity with an IC50 of 233 nM, and shows no measurable inhibition of recombinant human PAK2 at concentrations up to 10,000 nM[1].
BJG-05-039 (10 μM) exhibits a selective kinase binding profile, closely matching the selectivity of NVS-PAK1-1 (HY-100519) across a panel of 468 human kinases[1].
BJG-05-039 (1 μM; 5 h) induces strong downregulation of Lenalidomide (HY-A0003) off-target proteins RNF166, IKZF1, and IKZF3, but does not produce detectable PAK1 downregulation via global proteomic analysis[1].
BJG-05-039 (10 min) potently inhibits purified phosphorylated PAK1 with a Ki of 233 nM and shows minimal activity against purified phosphorylated PAK2 with a Ki of >10,000 nM[2].
BJG-05-039 inhibits MEK1 phosphorylation in cells with an EC50 of 10 nM[2].
BJG-05-039 (1 nM-10 μM; 4-24 h) induces selective, time-dependent, ubiquitin-proteasome system-dependent degradation of PAK1 (but not PAK2) in MCF7 and OVCAR3 cells, with maximal degradation at 10 nM, and achieves ~70% reduction of Nluc-PAK1 expression at 10 nM in HEK293 cells[1].
BJG-05-039 (10 nM) potently inhibits PAK1-dependent proliferative signaling (phospho-MEK1 S298 and phospho-ERK) in MCF7 and OVCAR3 cells, while 10 nM NVS-PAK1-1 has no measurable effect on these signaling readouts[1].
BJG-05-039 (72 h) potently reduces proliferation in PAK1-dependent MCF7 (EC50 = 0.086 μM) and OVCAR3 (EC50 = 0.1 μM) cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7 and OVCAR3 cells
-
Concentration:1 nM; 10 nM; 0.1 μM; 1 μM; 10 μM
-
Incubation Time:24 h
-
Result:Dose-dependently induced the degradation of PAK1, but not PAK2.
-
Cell Line:MCF7 and OVCAR3 (PAK1-dependent) cells, OMM1 and HEY-A8 (PAK2-dependent) cells
-
Concentration:tested in dose-response format
-
Incubation Time:72 h
-
Result:Exhibited potent anti-proliferative effects in PAK1-dependent MCF7 and OVCAR3 cells with EC50 values of 0.086 μM and 0.1 μM, respectively.
Showed no increased efficacy relative to NVS-PAK1-1 in PAK2-dependent OMM1 and HEY-A8 cells.
Chemical Information
-
CAS No. 3009849-06-0
-
Appearance Solid
-
Molecular Weight 821.29
-
Formula C41H44ClF3N8O5
-
Color Light yellow to yellow
-
SMILES
FC(F)CN1C2=C(C=C(Cl)C=C2)C(N[C@H]3CCN(C(NCCCCCCCCNC4=CC=CC(C(N5C6CCC(NC6=O)=O)=O)=C4C5=O)=O)C3)=NC7=CC(F)=CC=C17
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (121.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.04 mM); Suspended solution
This protocol yields a suspended solution of ≥ 2.5 mg/mL (saturation unknown). Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (289 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chow HY, et al. Development and Utility of a PAK1-Selective Degrader. Journal of medicinal chemistry. 2022 Dec 08;65(23):15627-15641. [Content Brief]
[2]. Johns DM, et al. Identification of a p21-activated kinase 1 (PAK1) inhibitor with 10-fold selectivity against PAK2. Bioorganic & medicinal chemistry letters. 2025 Nov 01;127:130307. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2176 mL | 6.0880 mL | 12.1760 mL | 30.4399 mL |
| 5 mM | 0.2435 mL | 1.2176 mL | 2.4352 mL | 6.0880 mL | |
| 10 mM | 0.1218 mL | 0.6088 mL | 1.2176 mL | 3.0440 mL | |
| 15 mM | 0.0812 mL | 0.4059 mL | 0.8117 mL | 2.0293 mL | |
| 20 mM | 0.0609 mL | 0.3044 mL | 0.6088 mL | 1.5220 mL | |
| 25 mM | 0.0487 mL | 0.2435 mL | 0.4870 mL | 1.2176 mL | |
| 30 mM | 0.0406 mL | 0.2029 mL | 0.4059 mL | 1.0147 mL | |
| 40 mM | 0.0304 mL | 0.1522 mL | 0.3044 mL | 0.7610 mL | |
| 50 mM | 0.0244 mL | 0.1218 mL | 0.2435 mL | 0.6088 mL | |
| 60 mM | 0.0203 mL | 0.1015 mL | 0.2029 mL | 0.5073 mL | |
| 80 mM | 0.0152 mL | 0.0761 mL | 0.1522 mL | 0.3805 mL | |
| 100 mM | 0.0122 mL | 0.0609 mL | 0.1218 mL | 0.3044 mL |
BJG-05-039 Related Classifications
HY-148821 Related Classifications
Powered by Bioz